Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker

Background: Minimal residual disease (MRD) tests provide early identification of hematologic relapse and timely management of acute myeloid leukemia (AML) patients. Approximately, 50% of AML patients do not have clonal chromosomal aberrations and categorize as a cytogenetically normal acute myeloid...

詳細記述

保存先:
書誌詳細
出版年:Int J Hematol Oncol Stem Cell Res
主要な著者: Alizad Ghandforoush, Nasrin, Chahardouli, Bahram, Rostami, Shahrbano, Ghadimi, Habibeh, Ghasemi, Ali, Alimoghaddam, Kamran, Ghavamzadeh, Ardeshir, Nadali, Fatemeh
フォーマット: Artigo
言語:Inglês
出版事項: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2016
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4969559/
https://ncbi.nlm.nih.gov/pubmed/27489590
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料